Regencell Bioscience Holdings Limited
NASDAQ:RGC
15.29 (USD) • At close July 16, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.746 | 0.77 | 0.604 | 0.026 | 0.01 | 0 |
| Gross Profit
| -0.746 | -0.77 | -0.604 | -0.026 | -0.01 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 1.066 | 1.582 | 2.512 | 0.438 | 0.386 | 0.228 |
| General & Administrative Expenses
| 3.217 | 4.429 | 5.08 | 0.941 | 0.312 | 0.159 |
| Selling & Marketing Expenses
| 0.125 | 0.263 | 0.025 | 0.002 | 0.114 | 0.004 |
| SG&A
| 2.925 | 4.692 | 5.106 | 0.943 | 0.426 | 0.163 |
| Other Expenses
| 0 | 0.211 | 0.023 | 0.035 | 0 | 0 |
| Operating Expenses
| 3.991 | 6.274 | 7.618 | 1.381 | 0.812 | 0.391 |
| Operating Income
| -4.737 | -6.274 | -7.618 | -1.381 | -0.812 | -0.391 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.374 | 0.211 | 0.023 | 0.035 | 0 | 0 |
| Income Before Tax
| -4.363 | -6.062 | -7.595 | -1.347 | -0.812 | -0.391 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 0 | 0 | -0 | -0 |
| Net Income
| -4.302 | -5.871 | -7.423 | -1.347 | -0.812 | -0.391 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.009 | -0.012 | -0.015 | -0.003 | -0.002 | -0.001 |
| EPS Diluted
| -0.009 | -0.012 | -0.015 | -0.003 | -0.002 | -0.001 |
| EBITDA
| -3.618 | -5.293 | -6.99 | -1.355 | -0.803 | -0.391 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |